Abstract
Summary
Filgotinib is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.
The global market for Filgotinib was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Filgotinib was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Filgotinib was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Filgotinib was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Filgotinib include Cayman Chemical, BioVision, Adooq Bioscience, Taiclone, Clearsynth, Biorbyt, APExBIO Technology, Selleck Chemicals and AbMole, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Filgotinib, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Filgotinib by region & country, by Type, and by Application.
The Filgotinib market size, estimations, and forecasts are provided in terms of sales volume (Kg) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Filgotinib.
Market Segmentation
By Company
Cayman Chemical
BioVision
Adooq Bioscience
Taiclone
Clearsynth
Biorbyt
APExBIO Technology
Selleck Chemicals
AbMole
BOC Sciences
TargetMol
Toronto Research Chemicals
J&K Scientific
Segment by Type:
Min Purity Less Than 98%
Min Purity 98%-99%
Min Purity More Than 99%
Segment by Application
Research
Medical
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Filgotinib manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Filgotinib in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Filgotinib in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global market for Filgotinib was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Filgotinib was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Filgotinib was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Filgotinib was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Filgotinib include Cayman Chemical, BioVision, Adooq Bioscience, Taiclone, Clearsynth, Biorbyt, APExBIO Technology, Selleck Chemicals and AbMole, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Filgotinib, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Filgotinib by region & country, by Type, and by Application.
The Filgotinib market size, estimations, and forecasts are provided in terms of sales volume (Kg) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Filgotinib.
Market Segmentation
By Company
Cayman Chemical
BioVision
Adooq Bioscience
Taiclone
Clearsynth
Biorbyt
APExBIO Technology
Selleck Chemicals
AbMole
BOC Sciences
TargetMol
Toronto Research Chemicals
J&K Scientific
Segment by Type:
Min Purity Less Than 98%
Min Purity 98%-99%
Min Purity More Than 99%
Segment by Application
Research
Medical
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Filgotinib manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Filgotinib in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Filgotinib in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
1.1 Filgotinib Product Introduction
1.2 Global Filgotinib Market Size Forecast
1.2.1 Global Filgotinib Sales Value (2019-2030)
1.2.2 Global Filgotinib Sales Volume (2019-2030)
1.2.3 Global Filgotinib Sales Price (2019-2030)
1.3 Filgotinib Market Trends & Drivers
1.3.1 Filgotinib Industry Trends
1.3.2 Filgotinib Market Drivers & Opportunity
1.3.3 Filgotinib Market Challenges
1.3.4 Filgotinib Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Filgotinib Players Revenue Ranking (2023)
2.2 Global Filgotinib Revenue by Company (2019-2024)
2.3 Global Filgotinib Players Sales Volume Ranking (2023)
2.4 Global Filgotinib Sales Volume by Company Players (2019-2024)
2.5 Global Filgotinib Average Price by Company (2019-2024)
2.6 Key Manufacturers Filgotinib Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Filgotinib Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Filgotinib
2.9 Filgotinib Market Competitive Analysis
2.9.1 Filgotinib Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Filgotinib Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Filgotinib as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Min Purity Less Than 98%
3.1.2 Min Purity 98%-99%
3.1.3 Min Purity More Than 99%
3.2 Global Filgotinib Sales Value by Type
3.2.1 Global Filgotinib Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Filgotinib Sales Value, by Type (2019-2030)
3.2.3 Global Filgotinib Sales Value, by Type (%) (2019-2030)
3.3 Global Filgotinib Sales Volume by Type
3.3.1 Global Filgotinib Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Filgotinib Sales Volume, by Type (2019-2030)
3.3.3 Global Filgotinib Sales Volume, by Type (%) (2019-2030)
3.4 Global Filgotinib Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Research
4.1.2 Medical
4.2 Global Filgotinib Sales Value by Application
4.2.1 Global Filgotinib Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Filgotinib Sales Value, by Application (2019-2030)
4.2.3 Global Filgotinib Sales Value, by Application (%) (2019-2030)
4.3 Global Filgotinib Sales Volume by Application
4.3.1 Global Filgotinib Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Filgotinib Sales Volume, by Application (2019-2030)
4.3.3 Global Filgotinib Sales Volume, by Application (%) (2019-2030)
4.4 Global Filgotinib Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Filgotinib Sales Value by Region
5.1.1 Global Filgotinib Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Filgotinib Sales Value by Region (2019-2024)
5.1.3 Global Filgotinib Sales Value by Region (2025-2030)
5.1.4 Global Filgotinib Sales Value by Region (%), (2019-2030)
5.2 Global Filgotinib Sales Volume by Region
5.2.1 Global Filgotinib Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Filgotinib Sales Volume by Region (2019-2024)
5.2.3 Global Filgotinib Sales Volume by Region (2025-2030)
5.2.4 Global Filgotinib Sales Volume by Region (%), (2019-2030)
5.3 Global Filgotinib Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Filgotinib Sales Value, 2019-2030
5.4.2 North America Filgotinib Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Filgotinib Sales Value, 2019-2030
5.5.2 Europe Filgotinib Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Filgotinib Sales Value, 2019-2030
5.6.2 Asia Pacific Filgotinib Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Filgotinib Sales Value, 2019-2030
5.7.2 South America Filgotinib Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Filgotinib Sales Value, 2019-2030
5.8.2 Middle East & Africa Filgotinib Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Filgotinib Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Filgotinib Sales Value
6.2.1 Key Countries/Regions Filgotinib Sales Value, 2019-2030
6.2.2 Key Countries/Regions Filgotinib Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Filgotinib Sales Value, 2019-2030
6.3.2 United States Filgotinib Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Filgotinib Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Filgotinib Sales Value, 2019-2030
6.4.2 Europe Filgotinib Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Filgotinib Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Filgotinib Sales Value, 2019-2030
6.5.2 China Filgotinib Sales Value by Type (%), 2023 VS 2030
6.5.3 China Filgotinib Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Filgotinib Sales Value, 2019-2030
6.6.2 Japan Filgotinib Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Filgotinib Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Filgotinib Sales Value, 2019-2030
6.7.2 South Korea Filgotinib Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Filgotinib Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Filgotinib Sales Value, 2019-2030
6.8.2 Southeast Asia Filgotinib Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Filgotinib Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Filgotinib Sales Value, 2019-2030
6.9.2 India Filgotinib Sales Value by Type (%), 2023 VS 2030
6.9.3 India Filgotinib Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Cayman Chemical
7.1.1 Cayman Chemical Company Information
7.1.2 Cayman Chemical Introduction and Business Overview
7.1.3 Cayman Chemical Filgotinib Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Cayman Chemical Filgotinib Product Offerings
7.1.5 Cayman Chemical Recent Development
7.2 BioVision
7.2.1 BioVision Company Information
7.2.2 BioVision Introduction and Business Overview
7.2.3 BioVision Filgotinib Sales, Revenue and Gross Margin (2019-2024)
7.2.4 BioVision Filgotinib Product Offerings
7.2.5 BioVision Recent Development
7.3 Adooq Bioscience
7.3.1 Adooq Bioscience Company Information
7.3.2 Adooq Bioscience Introduction and Business Overview
7.3.3 Adooq Bioscience Filgotinib Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Adooq Bioscience Filgotinib Product Offerings
7.3.5 Adooq Bioscience Recent Development
7.4 Taiclone
7.4.1 Taiclone Company Information
7.4.2 Taiclone Introduction and Business Overview
7.4.3 Taiclone Filgotinib Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Taiclone Filgotinib Product Offerings
7.4.5 Taiclone Recent Development
7.5 Clearsynth
7.5.1 Clearsynth Company Information
7.5.2 Clearsynth Introduction and Business Overview
7.5.3 Clearsynth Filgotinib Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Clearsynth Filgotinib Product Offerings
7.5.5 Clearsynth Recent Development
7.6 Biorbyt
7.6.1 Biorbyt Company Information
7.6.2 Biorbyt Introduction and Business Overview
7.6.3 Biorbyt Filgotinib Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Biorbyt Filgotinib Product Offerings
7.6.5 Biorbyt Recent Development
7.7 APExBIO Technology
7.7.1 APExBIO Technology Company Information
7.7.2 APExBIO Technology Introduction and Business Overview
7.7.3 APExBIO Technology Filgotinib Sales, Revenue and Gross Margin (2019-2024)
7.7.4 APExBIO Technology Filgotinib Product Offerings
7.7.5 APExBIO Technology Recent Development
7.8 Selleck Chemicals
7.8.1 Selleck Chemicals Company Information
7.8.2 Selleck Chemicals Introduction and Business Overview
7.8.3 Selleck Chemicals Filgotinib Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Selleck Chemicals Filgotinib Product Offerings
7.8.5 Selleck Chemicals Recent Development
7.9 AbMole
7.9.1 AbMole Company Information
7.9.2 AbMole Introduction and Business Overview
7.9.3 AbMole Filgotinib Sales, Revenue and Gross Margin (2019-2024)
7.9.4 AbMole Filgotinib Product Offerings
7.9.5 AbMole Recent Development
7.10 BOC Sciences
7.10.1 BOC Sciences Company Information
7.10.2 BOC Sciences Introduction and Business Overview
7.10.3 BOC Sciences Filgotinib Sales, Revenue and Gross Margin (2019-2024)
7.10.4 BOC Sciences Filgotinib Product Offerings
7.10.5 BOC Sciences Recent Development
7.11 TargetMol
7.11.1 TargetMol Company Information
7.11.2 TargetMol Introduction and Business Overview
7.11.3 TargetMol Filgotinib Sales, Revenue and Gross Margin (2019-2024)
7.11.4 TargetMol Filgotinib Product Offerings
7.11.5 TargetMol Recent Development
7.12 Toronto Research Chemicals
7.12.1 Toronto Research Chemicals Company Information
7.12.2 Toronto Research Chemicals Introduction and Business Overview
7.12.3 Toronto Research Chemicals Filgotinib Sales, Revenue and Gross Margin (2019-2024)
7.12.4 Toronto Research Chemicals Filgotinib Product Offerings
7.12.5 Toronto Research Chemicals Recent Development
7.13 J&K Scientific
7.13.1 J&K Scientific Company Information
7.13.2 J&K Scientific Introduction and Business Overview
7.13.3 J&K Scientific Filgotinib Sales, Revenue and Gross Margin (2019-2024)
7.13.4 J&K Scientific Filgotinib Product Offerings
7.13.5 J&K Scientific Recent Development
8 Industry Chain Analysis
8.1 Filgotinib Industrial Chain
8.2 Filgotinib Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Filgotinib Sales Model
8.5.2 Sales Channel
8.5.3 Filgotinib Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer